huge volume entering anp, page-27

Hi Ramses,
It is easy to be convincing when posting about a company which is part of a drug development whole business communities are excited about.

If I radiate confidence, it comes from having many people telling me that antisense drug development is not only much easier than traditional drug discovery ( how else could a mere 350 employees at ISIS create a pipeline of 26 drugs within such a short time frame ? ), it is therefore also cheaper and can support drug applications already in place without correlating side effects.

I agree, we are on a winner with this company and a unique play in a market which keeps undervaluing it.